Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Malignant and unspecified neoplasms gastrointestinal NEC

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44412   clinical trials with a EudraCT protocol, of which   7421   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    6 result(s) found for: Malignant and unspecified neoplasms gastrointestinal NEC. Displaying page 1 of 1.
    EudraCT Number: 2012-005578-79 Sponsor Protocol Number: ONC-2012-001 Start Date*: 2013-02-09
    Sponsor Name:ISTITUTO CLINICO HUMANITAS
    Full Title: A single-Arm Phase II Study of Tivantinib (ARQ 197) plus Cetuximab in EGFR inhibitor-resistant MET high subjects with locally advanced or metastatic colorectal cancer with wild-type KRAS
    Medical condition: Patients with advanced or metastatic wild type CRAS, MET high, CRC who have progressed on a previous EGFR inibitor based regimen
    Disease: Version SOC Term Classification Code Term Level
    14.1 10017947 - Gastrointestinal disorders 10017990 Malignant and unspecified neoplasms gastrointestinal NEC HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-001537-10 Sponsor Protocol Number: ASL608LIOM04 Start Date*: 2008-05-14
    Sponsor Name:G.O.N.O. - GRUPPO ONCOLOGICO NORD OVEST
    Full Title: A PHASE III RANDOMIZED TRIAL OF FOLFOXIRI + BEVACIZUMAB VERSUS FOLFIRI + BEVACIZUMAB AS FIRST-LINE TREATMENT FOR METASTATIC COLORECTAL CANCER
    Medical condition: colorectal cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10017990 Malignant and unspecified neoplasms gastrointestinal NEC HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-002522-36 Sponsor Protocol Number: CPDR001E2201 Start Date*: 2016-12-29
    Sponsor Name:Novartis Pharma AG
    Full Title: An open label phase II study to evaluate the efficacy and safety of PDR001 in patients with advanced or metastatic, well-differentiated, non-functional neuroendocrine tumors of pancreatic, gastroin...
    Medical condition: Advanced neuroendocrine tumor (NET) of pancreatic, GI lung origin or poorly-differentiated gastroenteropancreatic neuroendocrine carcinoma (GEP-NEC), that have progressed on prior treatment
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052399 Neuroendocrine tumour PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) GB (Prematurely Ended) DE (Prematurely Ended) ES (Completed) AT (Prematurely Ended) NL (Prematurely Ended) BE (Completed) FR (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-003902-14 Sponsor Protocol Number: EORTC-1741-GITCG Start Date*: Information not available in EudraCT
    Sponsor Name:European Organisation for Research and Treatment of Cancer
    Full Title: DKN-01/atezolizumab as second line treatment of biliarY tract cancer and in combiNAtion or not with paclitaxel as second line treatMent of esophagogastrIC cancer: a multi-center Phase II Trial
    Medical condition: Non-operable biliary tract cancer (BTC) and non-operable esophagogastric cancer (EGC) adenocarcinoma.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061203 Hepatobiliary neoplasm PT
    20.0 10019805 - Hepatobiliary disorders 10019817 Hepatobiliary neoplasms NEC HLT
    20.0 10019805 - Hepatobiliary disorders 10019811 Hepatobiliary neoplasms HLGT
    20.0 10019805 - Hepatobiliary disorders 10019805 Hepatobiliary disorders SOC
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10019814 Hepatobiliary neoplasms malignancy unspecified HLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10019815 Hepatobiliary neoplasms malignant and unspecified HLGT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029104 Neoplasms benign, malignant and unspecified (incl cysts and polyps) SOC
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10056267 Gastroesophageal cancer LLT
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062878 Gastrooesophageal cancer PT
    20.0 10017947 - Gastrointestinal disorders 10017812 Gastric neoplasms malignant HLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10017991 Gastrointestinal neoplasms malignant and unspecified HLGT
    20.0 10017947 - Gastrointestinal disorders 10017990 Malignant and unspecified neoplasms gastrointestinal NEC HLGT
    20.0 10017947 - Gastrointestinal disorders 10017947 Gastrointestinal disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CY (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2019-002974-29 Sponsor Protocol Number: HMH008 Start Date*: 2020-01-14
    Sponsor Name:Fundación de investigación de HM Hospitales
    Full Title: A phase II single arm trial evaluating the preliminary efficacy of the combination of 177Lu-DOTATATE and nivolumab in Grade 3 well-differentiated neuroendocrine tumours (NET) or poorly differentiat...
    Medical condition: Neuroendocrine neoplasms (Grade 3 well-differentiated neuroendocrine tumours (NET) or poorly differentiated neuroendocrine carcinomas (NEC))
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057270 Neuroendocrine carcinoma PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052399 Neuroendocrine tumour PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062476 Neuroendocrine tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-002453-11 Sponsor Protocol Number: CFTSp116 Start Date*: 2018-01-19
    Sponsor Name:The Christie NHS Foundation Trust
    Full Title: A multi-centre, randomised, parallel group, open-label, phase II, single-stage selection trial of nanoliposomal irinotecan (nal-IRI) and 5-fluorouracil (5-FU)/folinic acid or docetaxel as second-li...
    Medical condition: Poorly differentiated extra-pulmonary neuroendocrine carcinoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057270 Neuroendocrine carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Oct 16 08:38:14 CEST 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA